Ventyx Biosciences

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in Encinitas, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ventyx Biosciences reports Q1 losses, eyes market growth opportunities

Ventyx Biosciences navigates financial challenges with strong pipeline progress and strategic cash reserves.
Confidence in drug efficacy and proactive commercial planning position the company for market success.
Challenges from market competition and strategic decisions are balanced by growth opportunities and diversification.
Engagement with stakeholders and ongoing program advancements drive optimism for future growth and development.

Ventyx Biosciences progresses in Phase II trials amid commercial challenges

Ventyx Biosciences shows promising progress in Phase II trials for VTX958 and VTX002, with a focus on immune diseases like ulcerative colitis and psoriasis.
Challenges in commercial performance and trial diversity persist, but opportunities lie in upcoming Phase II results and potential expansion into new indications.
The company's financial performance reflects increased R&D investment, while strategic decisions on drug development and market positioning are crucial for future success.
Overall, Ventyx's innovative therapies and perseverance in trials position it for growth, pending successful Phase II outcomes and strategic adaptations.

Ventyx Biosciences reports promising Q1 results, eyes strategic partnerships

Ventyx Biosciences showcased strong performance in key inhibitors and IBD assets, despite facing financial challenges and the need to navigate regulatory complexities. The company's focus on innovation, upcoming trials, and potential partnerships positions them well for future growth and success in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On or about October 21, 2021, Ventyx conducted its initial public offering (“IPO”), selling over 9 million shares of common stock at $16.00 per share. On November 6, 202.

The Law Offices of Frank R. Cruz Announces Investigation of Ventyx Biosciences, Inc. (VTYX) on Behalf of Investors

NEW YORK, NY / ACCESSWIRE / March 6, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=69455&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Ventyx Biosciences, Inc. (VTYX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

NEW YORK , March 5, 2024 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant and/or traceable to the offering documents issued in connection with the Company's October 21, 2021 initial public offering (the "IPO" or "Offering"); and/or (ii) between October 21, 2021 and November 6, 2023, both dates inclusive (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than April 30, 2024.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTYX

NEW YORK--(BUSINESS WIRE)---- $VTYX #Investigation--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of those who acquired Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ:VTYX) securities during the period of October 21, 2021 through November 6, 2023, inclusive (“the Class Period”). Investors have until April 30, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. [C.

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Ventyx Biosciences, Inc. (VTYX) Investors

LOS ANGELES, CA / ACCESSWIRE / March 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ventyx Biosciences, Inc. ("Ventyx" or "the Company") (NASDAQ:VTYX) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents in connection with its initial public offering ("IPO") conducted on or about October 21, 2021 and/or between October 21, 2021 through November 6, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before April 30, 2024.

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses In Excess of $100,000 to Contact the Firm

SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that it will host a virtual investor event on Monday, March 11, 2024 from 11:00 a.m. to 12:30 p.m. ET.

Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant and/or traceable to the offering documents issued in connection with the Company's October 21, 2021 initial public offering (the “IPO” or “Offering”); and/or (ii) between October 21, 2021 and November 6, 2023, both dates inclusive (the “Class Period”). If you wish to serv.

ROSEN, A LEADING LAW FIRM, Encourages Ventyx Biosciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – VTYX

Ventyx to host virtual investor event on March 11 th to provide clinical updates on our NLRP3 portfolio and from the open-label extension of the VTX002 Phase 2 trial in ulcerative colitis

Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress

SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference.

Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

LOS ANGELES, CA / ACCESSWIRE / January 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ventyx Biosciences, Inc. ("Ventyx" or "the Company") (NASDAQ:VTYX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ventyx Biosciences, Inc. ("Ventyx" or "the Company") (NASDAQ:VTYX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm

SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the upcoming 35th Annual Piper Sandler Healthcare Conference.

Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) on behalf of Ventyx stockholders. Our investigation concerns whether Ventyx has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On November 6, 2023, STAT published an article regarding Ventyx's.

VENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ventyx Biosciences, Inc. on Behalf of Ventyx Stockholders and Encourages Investors to Contact the Firm

SAN DIEGO, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the upcoming Jefferies London Healthcare Conference.

Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference

LOS ANGELES, CA / ACCESSWIRE / November 9, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ventyx Biosciences, Inc. ("Ventyx" or "the Company") (NASDAQ:VTYX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm

Ventyx to provide updates across clinical-stage portfolio in the first quarter of 2024 Cash, cash equivalents and marketable securities of $300.8 million as of September 30, 2023 SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced financial results for the third quarter ended September 30, 2023, and highlighted recent pipeline and business progress. “We are committed to progressing our wholly-owned portfolio of novel small molecule drug candidates,” said Raju Mohan, Chief Executive Officer.

Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress

NEW YORK--(BUSINESS WIRE)---- $VTYX #classactionlawsuit--The law firm of Kirby McInerney LLP is investigating potential claims against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX). The investigation concerns whether Ventyx and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. On November 6, 2023, STAT published an article regarding Ventyx's decision to halt the development of an experimental drug for treating plaque psoriasis. Ven.

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Ventyx Biosciences, Inc. (VTYX)

Ventyx Biosciences, Inc. (VTYX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -86.57% in 4 Weeks, Here's Why Ventyx Biosciences, Inc. (VTYX) Looks Ripe for a Turnaround

Today, we look at Ventyx Biosciences, Inc., a clinical-stage biopharma company focused on developing small molecule products for inflammatory diseases. The company has now had two major trial disappointments in the span of a month, triggering a huge selloff in the shares. However, the company's pipeline still has a few "shots on goal" and the stock is now trading below net cash on the balance sheet.

Ventyx Biosciences Now Has 2 Strikes

Ventyx Biosciences scrapped a psoriasis drug that didn't pass muster in Phase 2 testing on Tuesday, and VTYX stock crashed more than 80%.

Ventyx Crashes 82% After Scrapping Two Studies On A Psoriasis Treatment Flop

Ventyx Biosciences (NASDAQ: VTYX ) stock is falling hard on Tuesday after the clinical-stage biopharmaceutical company released poor study results. These results come from a Phase 2 clinical trial of VTX958 in patients suffering from moderate to severe plaque psoriasis.

Why Is Ventyx Biosciences (VTYX) Stock Down 76% Today?

Shares of Ventyx Biosciences Inc. VTYX, -9.56% plunged 73.7% in premarket trading Tuesday, after the biopharmaceutical company said it has decided not to support further development of its plaque psoriasis and psoriatic arthritis treatments. The stock, which was the biggest decliner listed on major U.S. exchanges ahead of the open, was on track to suffer a record one-day selloff and open in record-low territory.

Ventyx Biosciences' stock suffering record plunge after psoriasis treatment trial fails to meet internal efficacy target

VTX958 225 mg BID and 300 mg BID doses achieved statistical significance on the primary endpoint (PASI 75) and all key secondary endpoints at Week 16

Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update

Ventyx Biosciences (VTYX) announces positive top-line data from a phase II study evaluating its pipeline candidate, VTX002, for treating moderate-to-severely active ulcerative colitis. Stock down.

Ventyx (VTYX) Down Despite Positive Ulcerative Colitis Study Data

Ventyx is a clinical-stage biotech that focuses on autoimmune disorders. The company's lead therapy candidate is VTX002 to treat moderate-to-severe ulcerative colitis.

News for Ventyx Biosciences Stock (VTYX)